Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) closed the day trading at $0.19 down -43.10% from the previous closing price of $0.33. In other words, the price has decreased by -$0.1409 from its previous closing price. On the day, 21620668 shares were traded.
Ratios:
For a better understanding of TNXP, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.02 and its Current Ratio is at 1.77. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 10.36M and an Enterprise Value of 4.59M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.77 while its Price-to-Book (P/B) ratio in mrq is 0.03. Its current Enterprise Value per Revenue stands at 1.15 whereas that against EBITDA is -0.04.
Stock Price History:
Over the past 52 weeks, TNXP has reached a high of $4.00, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is 0.3360, while the 200-Day Moving Average is calculated to be 0.7291.
Shares Statistics:
Over the past 3-months, TNXP traded about 1.46M shares per day on average, while over the past 10 days, TNXP traded about 3.78M shares per day. A total of 80.82M shares are outstanding, with a floating share count of 80.81M. Insiders hold about 0.01% of the company’s shares, while institutions hold 20.77% stake in the company. Shares short for TNXP as of Mar 15, 2024 were 967.03k with a Short Ratio of 0.66, compared to 596.5k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.65% and a Short% of Float of 1.65%.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$1.64 for the current quarter, with a high estimate of -$1.46 and a low estimate of -$1.83, while EPS last year was -$3.5. The consensus estimate for the next quarter is -$1.35, with high estimates of -$1.35 and low estimates of -$1.35.
Analysts are recommending an EPS of between -$4.49 and -$8.8 for the fiscal current year, implying an average EPS of -$6.64. EPS for the following year is -$3.14, with 3 analysts recommending between -$0.91 and -$5.83.
